The tumorigenic liver fluke Opisthorchis viverrini - multiple pathways to cancer

Trends in Parasitology

Volumn 28, Issue 10, 2012, Pages 395-407

  Sripa, Banchob ^a   Brindley, Paul J ^b   Mulvenna, Jason ^c   Laha, Thewarach ^a   Smout, Michael J ^c   Mairiang, Eimorn ^a   Bethony, Jeffrey M ^b   Loukas, Alex ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c JAMES COOK UNIVERSITY   (Australia)

Author keywords

Cholangiocarcinoma; Excretory secretory; Granulin; Liver cancer; Liver fluke; Opisthorchis; Periductal fibrosis; Wound healing

Indexed keywords

INTERLEUKIN 6; PRAZIQUANTEL; TOLL LIKE RECEPTOR 4; VACCINE;

APOPTOSIS; CHRONIC DISEASE; CLONORCHIASIS; DISEASE COURSE; DNA DAMAGE; FUNCTIONAL GENOMICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST PARASITE INTERACTION; HUMAN; IMMUNOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONHUMAN; OPISTHORCHIASIS; OPISTHORCHIS VIVERRINI; REVIEW; SCHISTOSOMA HEMATOBIUM; SQUAMOUS CELL CARCINOMA; WOUND HEALING;

ANIMALS; BILE DUCT NEOPLASMS; DEVELOPING COUNTRIES; HOST-PARASITE INTERACTIONS; HUMANS; OPISTHORCHIASIS; OPISTHORCHIS; RISK FACTORS;

CLONORCHIS SINENSIS; FASCIOLA HEPATICA; OPISTHORCHIS; OPISTHORCHIS VIVERRINI;

EID: 84866480274     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2012.07.006     Document Type: Review

References (121)

1. Lun Z.R., et al. Clonorchiasis: a key foodborne zoonosis in China. Lancet Infect. Dis. 2005, 5:31-41.
2. Hong S.T., Fang Y. Clonorchis sinensis and clonorchiasis, an update. Parasitol. Int. 2012, 61:17-24.
3. Keiser J., Utzinger J. Food-borne trematodiases. Clin. Microbiol. Rev. 2009, 22:466-483.
4. Mordvinov V.A., et al. Opisthorchis felineus and Metorchis bilis are the main agents of liver fluke infection of humans in Russia. Parasitol. Int. 2012, 61:25-31.
5. IARC Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 1994, 61:1-241.
6. Sithithaworn P., et al. The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitol. Int. 2012, 61:10-16.
7. Sripa B., et al. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007, 4:e201.
8. Thamavit W., et al. Strong promoting effect of Opisthorchis viverrini infection on dimethylnitrosamine-initiated hamster liver. Cancer Lett. 1994, 78:121-125.
9. Vatanasapt V.S., et al. Liver flukes and liver cancer. Cancer Surv. 1999, 33:313-343.
10. Thamavit W., et al. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res. 1978, 38:4634-4639.
11. Srivatanakul P., et al. Opisthorchis viverrini infestation and endogenous nitrosamines as risk factors for cholangiocarcinoma in Thailand. Int. J. Cancer 1991, 48:821-825.
12. Vatanasapt V., et al. Cholangiocarcinoma in north-east Thailand. Lancet 1990, 335:116-117.
13. Furst T., et al. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12:210-221.
14. Sayasone S., et al. Helminth and intestinal protozoa infections, multiparasitism and risk factors in Champasack province, Lao People's Democratic Republic. PLoS Negl. Trop. Dis. 2011, 5:e1037.
15. Forrer A., et al. Spatial distribution of, and risk factors for, Opisthorchis viverrini infection in southern Lao PDR. PLoS Negl. Trop. Dis. 2012, 6:e1481.
16. Viranuvatti V., et al. Retention cyst of liver caused by opisthorchiasis associated with carcinoma; case report. Am. J. Gastroenterol. 1955, 23:442-446.
17. Newton R.W., et al. Schistosomes and human cancer. Cancer Surv. 1999, 33:291-311.
18. Jongsuksuntigul P., Imsomboon T. Opisthorchiasis control in Thailand. Acta Trop. 2003, 88:229-232.
19. IARC Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr. Eval. Carcinog. Risks Hum. 1994, 61:121-175.
20. Loaharanu P., Sornmani S. Preliminary estimates of economic impact of liver fluke infection in Thailand and the feasibility of irradiation as a control measure. Southeast Asian J. Trop. Med. Public Health 1991, 22(Suppl.):384-390.
21. Andrews R.H., et al. Opisthorchis viverrini: an underestimated parasite in world health. Trends Parasitol. 2008, 24:497-501.
22. Bray F., et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012, 13:790-801.
23. Rebbeck T.R. Conquering cancer disparities: new opportunities for cancer epidemiology, biomarker, and prevention research. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1569-1571.
24. Rebbeck T.R., et al. Genetics, epidemiology, and cancer disparities: is it black and white?. J. Clin. Oncol. 2006, 24:2164-2169.
25. Bissell M.J., Radisky D. Putting tumors in context. Nat. Rev. Cancer 2001, 1:46-54.
26. Sripa B., et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology 2009, 50:1273-1281.
27. Sripa B., et al. Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl. Trop. Dis. 2012, 6:e1654.
28. Sripa B., Kaewkes S. Localisation of parasite antigens and inflammatory responses in experimental opisthorchiasis. Int. J. Parasitol. 2000, 30:735-740.
29. Venugopal P.G., et al. Activation and regulation of toll-like receptors (TLRs) by helminth parasites. Immunol. Res. 2009, 43:252-263.
30. Ninlawan K., et al. Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. Parasitol. Int. 2010, 59:616-621.
31. Pairojkul C., et al. Multistage carcinogenesis of liver-fluke-associated cholangiocarcinoma in Thailand. Princess Takamatsu Symp. 1991, 22:77-86.
32. Vatanasapt V., et al. Cancer survival in Khon Kaen, Thailand. IARC Sci. Publ. 1998, 145:123-134.
33. Schwartz L., et al. Cancer: the role of extracellular disease. Med. Hypotheses 2002, 58:340-346.
34. Moore M.A., et al. Early lesions induced by DHPN in Syrian golden hamsters: influence of concomitant Opisthorchis infestation, dehydroepiandrosterone or butylated hydroxyanisole administration. Carcinogenesis 1988, 9:1185-1189.
35. Mulvenna J., et al. The secreted and surface proteomes of the adult stage of the carcinogenic human liver fluke Opisthorchis viverrini. Proteomics 2010, 10:1063-1078.
36. Thuwajit C., et al. Increased cell proliferation of mouse fibroblast NIH-3T3 in vitro induced by excretory/secretory product(s) from Opisthorchis viverrini. Parasitology 2004, 129:455-464.
37. Bhamarapravati N., et al. Liver changes in hamsters infected with a liver fluke of man, Opisthorchis viverrini. Am. J. Trop. Med. Hyg. 1978, 27:787-794.
38. Laha T., et al. Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverrini. BMC Genomics 2007, 8:189.
39. Young N.D., et al. Unlocking the transcriptomes of two carcinogenic parasites, Clonorchis sinensis and Opisthorchis viverrini. PLoS Negl. Trop. Dis. 2010, 4:e719.
40. Daorueang D., et al. Secreted Opisthorchis viverrini glutathione S-transferase regulates cell proliferation through AKT and ERK pathways in cholangiocarcinoma. Parasitol. Int. 2012, 61:155-161.
41. Smout M.J., et al. A granulin-like growth factor secreted by the carcinogenic liver fluke, Opisthorchis viverrini, promotes proliferation of host cells. PLoS Pathog. 2009, 5:e1000611.
42. Smout M.J., et al. Expression, refolding and purification of Ov-GRN-1, a granulin-like growth factor from the carcinogenic liver fluke, that causes proliferation of mammalian host cells. Protein Expr. Purif. 2011, 79:263-270.
43. Bateman A., Bennett H.P. Granulins: the structure and function of an emerging family of growth factors. J. Endocrinol. 1998, 158:145-151.
44. Ong C.H., Bateman A. Progranulin (granulin-epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histol. Histopathol. 2003, 18:1275-1288.
45. Monami G., et al. Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res. 2006, 66:7103-7110.
46. Zanocco-Marani T., et al. Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Res. 1999, 59:5331-5340.
47. Frampton G., et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 2012, 61:268-277.
48. Jones M.B., et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin. Cancer Res. 2003, 9:44-51.
49. Kim Y.J., et al. Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis. Parasitol. Res. 2009, 104:1011-1016.
50. Bateman A., et al. Granulins, a novel class of peptide from leukocytes. Biochem. Biophys. Res. Commun. 1990, 173:1161-1168.
51. He Z., et al. Progranulin is a mediator of the wound response. Nat. Med. 2003, 9:225-229.
52. Kullavanijaya P., et al. Current status of infection-related gastrointestinal and hepatobiliary diseases in Thailand. Southeast Asian J. Trop. Med. Public Health 1999, 30:96-105.
53. Thamavit W., et al. Promotion of cholangiocarcinogenesis in the hamster liver by bile duct ligation after dimethylnitrosamine initiation. Carcinogenesis 1993, 14:2415-2417.
54. Kenny P.A., Bissell M.J. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int. J. Cancer 2003, 107:688-695.
55. Haddow A. Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing?. Adv. Cancer Res. 1972, 16:181-234.
56. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
57. Sripa J., et al. Secreted cysteine proteases of the carcinogenic liver fluke, Opisthorchis viverrini: regulation of cathepsin F activation by autocatalysis and trans-processing by cathepsin B. Cell. Microbiol. 2010, 12:781-795.
58. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9:628-638.
59. Thuwajit C., et al. Gene expression profiling defined pathways correlated with fibroblast cell proliferation induced by Opisthorchis viverrini excretory/secretory product. World J. Gastroenterol. 2006, 12:3585-3592.
60. Sripa B., et al. Opisthorchis viverrini and opisthorchiasis: the 21st century review. Acta Trop. 2003, 88:169-170.
61. Elkins D.B., et al. A high frequency of hepatobiliary disease and suspected cholangiocarcinoma associated with heavy Opisthorchis viverrini infection in a small community in north-east Thailand. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:715-719.
62. Elkins D.B., et al. Cross-sectional patterns of hepatobiliary abnormalities and possible precursor conditions of cholangiocarcinoma associated with Opisthorchis viverrini infection in humans. Am. J. Trop. Med. Hyg. 1996, 55:295-301.
63. Mairiang E., et al. Ultrasound Screening for Opisthorchis viverrini-associated cholangiocarcinomas: experience in an endemic area. Asian Pac. J. Cancer Prev. 2006, 7:431-433.
64. Mairiang E., et al. Relationship between intensity of Opisthorchis viverrini infection and hepatobiliary disease detected by ultrasonography. J. Gastroenterol. Hepatol. 1992, 7:17-21.
65. Mairiang E., et al. Reversal of biliary tract abnormalities associated with Opisthorchis viverrini infection following praziquantel treatment. Trans. R. Soc. Trop. Med. Hyg. 1993, 87:194-197.
66. Mairiang E., Mairiang P. Clinical manifestation of opisthorchiasis and treatment. Acta Trop. 2003, 88:221-227.
67. Mairiang E., et al. Ultrasonography assessment of hepatobiliary abnormalities in 3359 subjects with Opisthorchis viverrini infection in endemic areas of Thailand. Parasitol. Int. 2012, 61:208-211.
68. Flavell D.J., et al. Opisthorchis viverrini: the relationship between egg production, worm size and intensity of infection in the hamster. Trans. R. Soc. Trop. Med. Hyg. 1983, 77:538-545.
69. Loilome W., et al. Altered gene expression in Opisthorchis viverrini-associated cholangiocarcinoma in hamster model. Mol. Carcinog. 2006, 45:279-287.
70. Nithikathkul C., et al. Early stage biliary and intrahepatic migration of Opisthorchis viverrini in the golden hamster. J. Helminthol. 2007, 81:39-41.
71. Sirisinha S., et al. Humoral immune responses in hamsters infected with Opisthorchis viverrini. Southeast Asian J. Trop. Med. Public Health 1983, 14:243-251.
72. Boonmars T., et al. Apoptosis-related gene expression in hamster opisthorchiasis post praziquantel treatment. Parasitol. Res. 2008, 102:447-455.
73. Pinlaor S., et al. iNOS-dependent DNA damage via NF-kappaB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel. Int. J. Cancer 2006, 119:1067-1072.
74. Pinlaor S., et al. Oxidative and nitrative stress in Opisthorchis viverrini-infected hamsters: an indirect effect after praziquantel treatment. Am. J. Trop. Med. Hyg. 2008, 78:564-573.
75. Pungpak S., et al. Opisthorchis viverrini infection in Thailand: studies on the morbidity of the infection and resolution following praziquantel treatment. Am. J. Trop. Med. Hyg. 1997, 56:311-314.
76. Goydos J.S., et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann. Surg. 1998, 227:398-404.
77. Balkwill F., et al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
78. de Visser K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6:24-37.
79. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 2008, 14:109-119.
80. Gatto M., et al. Cholangiocarcinoma: update and future perspectives. Dig. Liver Dis. 2010, 42:253-260.
81. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr. Opin. Gastroenterol. 2009, 25:279-284.
82. Briggs C.D., et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur. J. Cancer 2009, 45:33-47.
83. Morris-Stiff G., et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig. Surg. 2008, 25:126-132.
84. Patel A.H., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 2000, 95:204-207.
85. Lempinen M., et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J. Hepatol. 2007, 47:677-683.
86. Bamrungphon W., et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007, 247:301-308.
87. Chapman M.H., et al. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J. Clin. Exp. Hepatol. 2011, 1:6-12.
88. Uenishi T., et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 2008, 15:583-589.
89. Boonjaraspinyo S., et al. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol. Int. 2012, 61:145-150.
90. Techasen A., et al. Opisthorchis viverrini-antigen induces expression of MARCKS during inflammation-associated cholangiocarcinogenesis. Parasitol. Int. 2012, 61:140-144.
91. Loilome W., et al. Expression of oxysterol binding protein isoforms in opisthorchiasis-associated cholangiocarcinoma: a potential molecular marker for tumor metastasis. Parasitol. Int. 2012, 61:136-139.
92. Nair S.S., et al. Inflammatory response to liver fluke Opisthorchis viverrini in mice depends on host master coregulator MTA1, a marker for parasite-induced cholangiocarcinoma in humans. Hepatology 2011, 54:1388-1397.
93. Khoontawad J., et al. Proteomic identification of peroxiredoxin 6 for host defence against Opisthorchis viverrini infection. Parasite Immunol. 2010, 32:314-323.
94. Thanan R., et al. Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine in patients with parasite infection and effect of antiparasitic drug in relation to cholangiocarcinogenesis. Cancer Epidemiol. Biomarkers Prev. 2008, 17:518-524.
95. Yonglitthipagon P., et al. Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int. J. Parasitol. 2010, 40:1203-1212.
96. Yonglitthipagon P., et al. Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum. Pathol. 2012, 10.1016/j.humpath.2011.11.021.
97. Latterich M., et al. Proteomics: new technologies and clinical applications. Eur. J. Cancer 2008, 44:2737-2741.
98. Fu Q., et al. Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin. Appl. 2010, 4:271-284.
99. Wang X., et al. The draft genome of the carcinogenic human liver fluke Clonorchis sinensis. Genome Biol. 2011, 12:R107.
100. Kaewkong W., et al. Genome size estimation of liver fluke Opisthorchis viverrini by real-time polymerase chain reaction based method. Parasitol. Int. 2012, 61:77-80.
101. Kaewkong W., et al. Chromosomes and karyotype analysis of a liver fluke, Opisthorchis viverrini, by scanning electron microscopy. Parasitol. Int. 2012, 61:504-507.
102. Rinaldi G., et al. Development of functional genomic tools in trematodes: RNA interference and luciferase reporter gene activity in Fasciola hepatica. PLoS Negl. Trop. Dis. 2008, 2:e260.
103. Rinaldi G., et al. RNA interference targeting leucine aminopeptidase blocks hatching of Schistosoma mansoni eggs. Mol. Biochem. Parasitol. 2009, 167:118-126.
104. Sripa J., et al. RNA interference targeting cathepsin B of the carcinogenic liver fluke, Opisthorchis viverrini. Parasitol. Int. 2011, 60:283-288.
105. Soukhathammavong P., et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. Lancet Infect. Dis. 2011, 11:110-118.
106. Frazer I.H., et al. Prevention and treatment of papillomavirus-related cancers through immunization. Annu. Rev. Immunol. 2011, 29:111-138.
107. Xiao S., et al. The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, Necator americanus. Exp. Parasitol. 2008, 118:32-40.
108. Quan F.S., et al. Resistance to reinfection in rats induced by irradiated metacercariae of Clonorchis sinensis. Mem. Inst. Oswaldo Cruz 2005, 100:549-554.
109. Zhou Z., et al. Oral administration of a Bacillus subtilis spore-based vaccine expressing Clonorchis sinensis tegumental protein 22.3 kDa confers protection against Clonorchis sinensis. Vaccine 2008, 26:1817-1825.
110. Lee J.S., et al. Vaccination with DNA encoding cysteine proteinase confers protective immune response to rats infected with Clonorchis sinensis. Vaccine 2006, 24:2358-2366.
111. Kasny M., et al. Chapter 4. Peptidases of trematodes. Adv. Parasitol. 2009, 69:205-297.
112. Abdulla M.H., et al. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 2007, 4:e14.
113. Kenter G.G., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361:1838-1847.
114. Hotez P.J., et al. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol. 2010, 8:814-826.
115. Haswell-Elkins M.R., et al. Immune responsiveness and parasite-specific antibody levels in human hepatobiliary disease associated with Opisthorchis viverrini infection. Clin. Exp. Immunol. 1991, 84:213-218.
116. Pinlaor S., et al. Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini: a model of inflammation-mediated carcinogenesis. Nitric Oxide 2004, 11:175-183.
117. Pinlaor S., et al. Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7,8-dihydro-2'-deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. Carcinogenesis 2004, 25:1535-1542.
118. Thamavit W., et al. Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic Praziquantel lacks carcinogenic potential. Carcinogenesis 1992, 13:309-311.
119. Keiser J., Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin. Pharmacother. 2004, 5:1711-1726.
120. Loukas A., et al. Vaccinomics for the major blood feeding helminths of humans. OMICS 2011, 15:567-577.
121. Smout M.J., et al. Infection with the carcinogenic human liver fluke, Opisthorchis viverrini. Mol. Biosyst. 2011, 7:1367-1375.